Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2009 1
2015 1
2016 2
2018 1
2021 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Early Administration of Bamlanivimab in Combination with Etesevimab Increases the Benefits of COVID-19 Treatment: Real-World Experience from the Liguria Region.
Vena A, Cenderello G, Balletto E, Mezzogori L, Santagostino Barbone A, Berruti M, Ball L, Battaglini D, Bonsignore A, Dentone C, Giacobbe DR, Eldin TK, Mikulska M, Rebesco B, Robba C, Scintu A, Stimamiglio A, Taramasso L, Pelosi P, Artioli S, Bassetti M. Vena A, et al. Among authors: rebesco b. J Clin Med. 2021 Oct 13;10(20):4682. doi: 10.3390/jcm10204682. J Clin Med. 2021. PMID: 34682805 Free PMC article.
Targeting the Epidermal Growth Factor Receptor Can Counteract the Inhibition of Natural Killer Cell Function Exerted by Colorectal Tumor-Associated Fibroblasts.
Costa D, Venè R, Benelli R, Romairone E, Scabini S, Catellani S, Rebesco B, Mastracci L, Grillo F, Minghelli S, Loiacono F, Zocchi MR, Poggi A. Costa D, et al. Among authors: rebesco b. Front Immunol. 2018 May 29;9:1150. doi: 10.3389/fimmu.2018.01150. eCollection 2018. Front Immunol. 2018. PMID: 29910806 Free PMC article.
High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients.
Guolo F, Minetto P, Clavio M, Miglino M, Di Grazia C, Ballerini F, Pastori G, Guardo D, Colombo N, Kunkl A, Fugazza G, Rebesco B, Sessarego M, Lemoli RM, Bacigalupo A, Gobbi M. Guolo F, et al. Among authors: rebesco b. Am J Hematol. 2016 Aug;91(8):755-62. doi: 10.1002/ajh.24391. Epub 2016 Jun 15. Am J Hematol. 2016. PMID: 27084986 Free article.